Psychiatry research · 2024
Maternal vitamin B12 during pregnancy and schizophrenia in offspring.
СтатьяПоддержка исследования: вне правительства СШАПоддержка NIH: внешняя программаНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sourander Andre, Silwal Sanju, Surcel Heljä-Marja, Hinkka-Yli-Salomäki Susanna, Cheslack-Postava Keely, Upadhyaya Subina, McKeague Ian W, Brown Alan S
Аннотация
BACKGROUND: Maternal nutritional deficiency is linked with several adverse outcomes in offspring but the link between maternal vitamin B12 levels and offspring schizophrenia remains unexplored.
METHODS: In this nationwide population-based nested case-control design, 1145 schizophrenia cases were born between 1987-1997 and diagnosed by 2017 and each case were matched with a control. Maternal vitamin B12 levels during the first and early second trimesters of pregnancy were measured using chemiluminescence microparticle immunoassay from maternal sera. Conditional logistic regression was used to examine the association between maternal vitamin B12 levels and offspring schizophrenia.
RESULTS: Low maternal vitamin B12 levels were not associated with offspring schizophrenia in unadjusted (OR 1.04, 95% CI 0.88-1.24) or adjusted analyses (aOR 1.14, 95% CI 0.95-1.37). When analyzed by quintiles, no significant association was observed between the lowest versus highest quintile of maternal vitamin B12 levels and schizophrenia in unadjusted (OR 1.01, 95% CI 0.78-1.30) or adjusted analyses (OR 0.89, 95% CI 0.68-1.17).
CONCLUSION: Maternal vitamin B12 levels in early pregnancy were not associated with offspring schizophrenia. Future studies measuring both genetic and environmental factors are required to elucidate the role of maternal vitamin B12 deficiency in schizophrenia and its potential pathways to influence schizophrenia in offspring.
METHODS: In this nationwide population-based nested case-control design, 1145 schizophrenia cases were born between 1987-1997 and diagnosed by 2017 and each case were matched with a control. Maternal vitamin B12 levels during the first and early second trimesters of pregnancy were measured using chemiluminescence microparticle immunoassay from maternal sera. Conditional logistic regression was used to examine the association between maternal vitamin B12 levels and offspring schizophrenia.
RESULTS: Low maternal vitamin B12 levels were not associated with offspring schizophrenia in unadjusted (OR 1.04, 95% CI 0.88-1.24) or adjusted analyses (aOR 1.14, 95% CI 0.95-1.37). When analyzed by quintiles, no significant association was observed between the lowest versus highest quintile of maternal vitamin B12 levels and schizophrenia in unadjusted (OR 1.01, 95% CI 0.78-1.30) or adjusted analyses (OR 0.89, 95% CI 0.68-1.17).
CONCLUSION: Maternal vitamin B12 levels in early pregnancy were not associated with offspring schizophrenia. Future studies measuring both genetic and environmental factors are required to elucidate the role of maternal vitamin B12 deficiency in schizophrenia and its potential pathways to influence schizophrenia in offspring.